Lansoprazole Teva

Lansoprazole, the active ingredient in Lansoprazole Teva, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid production and is indicated for the treatment of gastro‑oesophageal reflux disease, peptic ulcer disease, and as part of Helicobacter pylori eradication regimens in adult patients.

GNH USA supplies Lansoprazole Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, with established distribution networks and regulatory expertise across EU and global markets for a broad range of therapeutic needs.

Lansoprazole is a proton pump inhibitor used to manage conditions associated with excess gastric acid secretion.

- Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and esophageal irritation by reducing acid exposure. - Peptic ulcer disease: promotes healing of gastric and duodenal ulcers through sustained acid suppression. - Helicobacter pylori eradication: used in combination therapy to increase eradication rates by creating a less acidic gastric environment.

Lansoprazole may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild, transient headache reported by some patients. - Diarrhea: loose stools occurring during early treatment. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach region. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis associated with altered gut flora. - Acute interstitial nephritis: inflammation of kidney interstitium requiring medical attention. - Hypomagnesemia: low serum magnesium levels that may cause muscle cramps or arrhythmias. - Stevens‑Johnson syndrome: rare severe skin reaction with blistering and mucosal involvement.

Before prescribing Lansoprazole, clinicians should consider several precautionary measures to ensure safe use.

- Assess renal function: dose adjustment may be required in severe renal impairment. - Evaluate for CYP2C19 polymorphisms: altered metabolism can affect drug exposure. - Monitor long‑term use: prolonged therapy has been linked to increased risk of fractures and vitamin B12 deficiency. - Use with caution in patients with liver disease: hepatic impairment may increase systemic exposure. - Discontinue before surgery: consider stopping the drug prior to procedures requiring gastric acidity. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Lansoprazole can affect the pharmacokinetics of several concomitant medicines, requiring attention to potential interactions.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect due to impaired activation. - Atazanavir: decreased absorption leading to loss of antiviral efficacy. - Dasatinib: lowered plasma concentrations compromising cancer therapy.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring more frequent monitoring. - Methotrexate: reduced renal clearance may raise toxicity risk. - Digoxin: modest increase in serum levels, monitor for signs of toxicity.